Sustained and targeted delivery of checkpoint inhibitors by metal-organic frameworks for cancer immunotherapy
AuthorsAlsaiari, Shahad K.
Qutub, Somayah S.
Aldehaiman, Mansour M.
Alyami, Mram Z.
Alsaiari, Shahad K.
KAUST DepartmentBioscience Program
Biological and Environmental Sciences and Engineering (BESE) Division
Smart Hybrid Materials (SHMs) Laboratory, Advanced Membranes and Porous Materials Center, King Abdullah University of Science and Technology (KAUST), Thuwal 23955-6900, Saudi Arabia.
Chemical Science Program
Advanced Membranes and Porous Materials Research Center
Physical Science and Engineering (PSE) Division
Permanent link to this recordhttp://hdl.handle.net/10754/667120
MetadataShow full item record
AbstractThe major impediments to the implementation of cancer immunotherapies are the sustained immune effect and the targeted delivery of these therapeutics, as they have life-threatening adverse effects. In this work, biomimetic metal-organic frameworks [zeolitic imidazolate frameworks (ZIFs)] are used for the controlled delivery of nivolumab (NV), a monoclonal antibody checkpoint inhibitor that was U.S. Food and Drug Administration–approved back in 2014. The sustained release behavior of NV-ZIF has shown a higher efficacy than the naked NV to activate T cells in hematological malignancies. The system was further modified by coating NV-ZIF with cancer cell membrane to enable tumor-specific targeted delivery while treating solid tumors. We envisage that such a biocompatible and biodegradable immunotherapeutic delivery system may promote the development and the translation of hybrid superstructures into smart and personalized delivery platforms.
CitationAlsaiari, S. K., Qutub, S. S., Sun, S., Baslyman, W., Aldehaiman, M., Alyami, M., … Khashab, N. M. (2021). Sustained and targeted delivery of checkpoint inhibitors by metal-organic frameworks for cancer immunotherapy. Science Advances, 7(4), eabe7174. doi:10.1126/sciadv.abe7174
SponsorsWe thank R. Langer, Institute Professor, MIT, for feedback and comments. We acknowledge H. Alrabiah, Associate Professor at the Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University and H. I. Aljohar, Assistant Professor at the Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University for providing nivolumab.
This work was funded by the King Abdulaziz City for Science and Technology (KACST) through the MERS-CoV research grant program (number 20-0004), which is a part of the Targeted Research Program (TRP).
Except where otherwise noted, this item's license is described as The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S.Government Works. Distributed under a Creative Commons Attribution Non Commercial License 4.0 (CC BY-NC).